Curated News
By: NewsRamp Editorial Staff
July 27, 2026

VERAXA Biotech and OmniAb Advance Targeted Cancer Therapy

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • VERAXA Biotech advances VXA-222 bsADC with OmniAb, positioning for edge in precision solid tumor treatment.
  • VXA-222 uses an AND-gate approach targeting two antigens, with OmniAb's discovery and VERAXA's linker tech.
  • This collaboration aims to improve cancer therapy precision, potentially reducing side effects for patients.
  • VXA-222 is a bispecific antibody-drug conjugate designed to hit two tumor targets with one molecule.

Impact - Why it Matters

This news matters because it represents progress in developing more precise cancer treatments. VXA-222 uses an 'AND-gate' mechanism that may reduce side effects by only activating in the presence of two specific tumor antigens, potentially improving outcomes for patients with solid tumors. The collaboration between VERAXA and OmniAb accelerates the development of next-generation antibody-drug conjugates, which could offer new hope for difficult-to-treat cancers. For investors, the milestone signals that the partnership is delivering on its goals, potentially increasing the value of VERAXA's pipeline and its stock (VRXA).

Summary

VERAXA Biotech (NASDAQ: VRXA) has announced a significant milestone in its collaboration with OmniAb (NASDAQ: OABI), advancing its bispecific antibody-drug conjugate (bsADC) program, VXA-222. The program targets solid tumors using an innovative “AND-gate” approach that requires two tumor antigens to be present for the drug to activate, potentially improving precision and reducing off-target effects. OmniAb successfully completed its discovery work, allowing the program to move into its next phase. This collaboration, initiated in May 2025, leverages OmniAb’s antibody discovery technologies, including its OmniClic™ platform, alongside VERAXA’s proprietary linker technology and conjugation expertise. Under the agreement, VERAXA holds exclusive rights to develop and commercialize products from the collaboration, while OmniAb receives a share of specified revenue. The achievement marks a key step toward bringing a more targeted therapy to patients with solid tumors, addressing a critical need in oncology.

VERAXA Biotech, founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), is building a premier engine for next-generation antibody-based therapeutics, including bispecific T cell engagers and bispecific ADCs like VXA-222. The company’s pipeline is driven by transformative technologies and quality-by-design principles, aiming to advance its proprietary BiTAC® formats into clinical development. The success of the VXA-222 program underscores VERAXA’s commitment to precision oncology and its ability to collaborate effectively with partners like OmniAb to accelerate drug discovery. For more details, the full press release is available at https://ibn.fm/qMRuJ. Investors can stay updated on VERAXA’s progress via its newsroom at http://ibn.fm/VRXA.

BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, reported this news. BioMedWire focuses on the latest developments in Biotech, Biomedical Sciences, and Life Sciences, offering services such as press release enhancement, social media distribution, and editorial syndication to over 5,000 outlets. The platform is part of a broader network that helps companies reach investors, consumers, and the public. This announcement highlights the growing interest in precision cancer therapies and the collaborative efforts driving innovation in the biotech sector.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, VERAXA Biotech and OmniAb Advance Targeted Cancer Therapy

blockchain registration record for this content.